Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

BiltRx vs FuturHealth

BiltRx
Graded #57

Higher grade

vs+9.700000000000003
FuturHealth
Graded #215

Lower grade

The verdict

BiltRx takes it — 75.3/100 to 65.6/100.

BiltRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. BiltRx is a US health-optimization telehealth platform spanning men's health, women's health, aesthetics and weight loss that offers compounded and brand-name GLP-1 medications.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBiltRx +31
91
60
Dose & formulationBiltRx +4
85
81
Clinical oversightBiltRx +7
74
67
Labs & monitoringFuturHealth +9
52
61
FulfillmentBiltRx +9
71
62
Contract termsEven
55
55
BiltRx · left barFuturHealth · right bar

The numbers

MetricBiltRxFuturHealth
WeighScore75.3/10065.6/100
GradeCC
Scorecard rank#57#215
Semaglutide$125/mo (all doses, compounded)$199/mo (compounded)
Tirzepatide$129/mo (all doses, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
BiltRx

Graded #57 · C

Strengths

  • Very low starting prices (semaglutide from 125 dollars, tirzepatide from 129 dollars)
  • LegitScript verified and HIPAA compliant
  • Names its 503A compounding pharmacies (Boothwyn and Southend)
  • Offers both compounded and brand-name GLP-1 options

Where it loses points

  • Covered states are behind a check-availability gate, not listed
  • Starting prices may rise depending on plan and dose
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard